Cargando...
Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR
Rationale: Combination lumacaftor/ivacaftor has been shown to improve lung function and other endpoints in patients aged 12 years and older with cystic fibrosis and homozygous for F508del-CFTR, but it has not been assessed in younger patients. Objectives: In this open-label phase III trial, we evalu...
Gardado en:
| Publicado en: | Am J Respir Crit Care Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Thoracic Society
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5440888/ https://ncbi.nlm.nih.gov/pubmed/27805836 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1164/rccm.201608-1754OC |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|